📰 Thomas Shrader News
Page 2 - Thomas Shrader News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Thomas Shrader. Real-time updates on events, politics, business and more.
November 4, 2022
Taking a look at advanced analytics through eight games
October 18, 2022
Tiyan “Pop” Bush made a name for himself as a high-flying linebacker with the Port Charlotte Pirates over half a decade ago, and he’s still giving opponents a reason to
October 11, 2022
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a clinical-stage biopharmaceutical company that discovers and develops therapies for the treatment of Alzheimer’s disease.
June 10, 2022
Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report.
May 6, 2022
ALDX earnings call for the period ending March 31, 2022.
March 18, 2022
ALDX earnings call for the period ending December 31, 2021.
August 5, 2021
Operator Good day. Thank you for standing by, and welcome to the G1 Therapeutics Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] I would now like to turn the conference over to your host, Mr. Will Roberts. Please go ahead, sir. William Roberts -- Vice President of Investor Relations & Corporate Communications T...
August 4, 2021
Operator Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions]. Following the presentation, there will be a question-and-answer session. [Operator Instructions] I would now like to hand the conference over to Ben Church, Investor Relations and Corporate Communications at Esperion. Please go ahead, sir. Benjamin Church -- Head, Corporate Communications & Investor Relations Thank you, operator. Good morning and welcome to Esperions Second Quarter 2021 Financial Re...
April 25, 2021
Markets BTIG analyst Thomas Shrader maintained a Hold rating on Biogen (BIIB – Research Report) on April 22. The company’s shares closed last Friday at $262.63. According to TipRanks.com, Shrader is a 4-star analyst with an average return of 18.6% and a 41.2% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics, Stoke Therapeutics, and Gain Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bi...
March 17, 2021
Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firms Thomas Shrader upgrades Biogens stock from Hold to Buy with a price target boosted from $300 to $415. First, there have been no news reports on the "gigantic" aducanumab phase 3 trial, which started in... Read More... Dont Miss Any Updates! News Directly in Your Inbox Subscribe to: